Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 68

1.

Epigenetic downregulation of the DNA repair gene MED1/MBD4 in colorectal and ovarian cancer.

Howard JH, Frolov A, Tzeng CW, Stewart A, Midzak A, Majmundar A, Godwin A, Heslin M, Bellacosa A, Arnoletti JP.

Cancer Biol Ther. 2009 Jan;8(1):94-100.

2.

Screening for genomic fragments that are methylated specifically in colorectal carcinoma with a methylated MLH1 promoter.

Koinuma K, Kaneda R, Toyota M, Yamashita Y, Takada S, Choi YL, Wada T, Okada M, Konishi F, Nagai H, Mano H.

Carcinogenesis. 2005 Dec;26(12):2078-85.

3.

Somatic frameshift mutations in the MBD4 gene of sporadic colon cancers with mismatch repair deficiency.

Bader S, Walker M, Hendrich B, Bird A, Bird C, Hooper M, Wyllie A.

Oncogene. 1999 Dec 23;18(56):8044-7.

4.

NGX6 gene mediated by promoter methylation as a potential molecular marker in colorectal cancer.

Liu M, Peng Y, Wang X, Guo Q, Shen S, Li G.

BMC Cancer. 2010 Apr 27;10:160. doi: 10.1186/1471-2407-10-160.

5.

Role of MED1 (MBD4) Gene in DNA repair and human cancer.

Bellacosa A.

J Cell Physiol. 2001 May;187(2):137-44. Review.

PMID:
11267993
6.

Promoter methylation of ITF2, but not APC, is associated with microsatellite instability in two populations of colorectal cancer patients.

Savio AJ, Daftary D, Dicks E, Buchanan DD, Parfrey PS, Young JP, Weisenberger D, Green RC, Gallinger S, McLaughlin JR, Knight JA, Bapat B.

BMC Cancer. 2016 Feb 17;16:113. doi: 10.1186/s12885-016-2149-9.

7.

Involvement of MBD4 inactivation in mismatch repair-deficient tumorigenesis.

Tricarico R, Cortellino S, Riccio A, Jagmohan-Changur S, Van der Klift H, Wijnen J, Turner D, Ventura A, Rovella V, Percesepe A, Lucci-Cordisco E, Radice P, Bertario L, Pedroni M, Ponz de Leon M, Mancuso P, Devarajan K, Cai KQ, Klein-Szanto AJ, Neri G, Møller P, Viel A, Genuardi M, Fodde R, Bellacosa A.

Oncotarget. 2015 Dec 15;6(40):42892-904. doi: 10.18632/oncotarget.5740.

8.

Biphasic kinetics of the human DNA repair protein MED1 (MBD4), a mismatch-specific DNA N-glycosylase.

Petronzelli F, Riccio A, Markham GD, Seeholzer SH, Stoerker J, Genuardi M, Yeung AT, Matsumoto Y, Bellacosa A.

J Biol Chem. 2000 Oct 20;275(42):32422-9.

9.

The base excision repair enzyme MED1 mediates DNA damage response to antitumor drugs and is associated with mismatch repair system integrity.

Cortellino S, Turner D, Masciullo V, Schepis F, Albino D, Daniel R, Skalka AM, Meropol NJ, Alberti C, Larue L, Bellacosa A.

Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):15071-6.

10.

Correlation between hypermethylation of the RASSF2A promoter and K-ras/BRAF mutations in microsatellite-stable colorectal cancers.

Park HW, Kang HC, Kim IJ, Jang SG, Kim K, Yoon HJ, Jeong SY, Park JG.

Int J Cancer. 2007 Jan 1;120(1):7-12.

11.

Frameshift mutations in the MBD4/MED1 gene in primary gastric cancer with high-frequency microsatellite instability.

Yamada T, Koyama T, Ohwada S, Tago K, Sakamoto I, Yoshimura S, Hamada K, Takeyoshi I, Morishita Y.

Cancer Lett. 2002 Jul 8;181(1):115-20.

PMID:
12430186
12.
13.

Investigation of the substrate spectrum of the human mismatch-specific DNA N-glycosylase MED1 (MBD4): fundamental role of the catalytic domain.

Petronzelli F, Riccio A, Markham GD, Seeholzer SH, Genuardi M, Karbowski M, Yeung AT, Matsumoto Y, Bellacosa A.

J Cell Physiol. 2000 Dec;185(3):473-80.

PMID:
11056019
14.

Epigenetic silencing of HOPX promotes cancer progression in colorectal cancer.

Katoh H, Yamashita K, Waraya M, Margalit O, Ooki A, Tamaki H, Sakagami H, Kokubo K, Sidransky D, Watanabe M.

Neoplasia. 2012 Jul;14(7):559-71.

15.

Alcohol dehydrogenase, iron containing, 1 promoter hypermethylation associated with colorectal cancer differentiation.

Tae CH, Ryu KJ, Kim SH, Kim HC, Chun HK, Min BH, Chang DK, Rhee PL, Kim JJ, Rhee JC, Kim YH.

BMC Cancer. 2013 Mar 22;13:142. doi: 10.1186/1471-2407-13-142.

16.

Epigenetic silencing of miR-137 is an early event in colorectal carcinogenesis.

Balaguer F, Link A, Lozano JJ, Cuatrecasas M, Nagasaka T, Boland CR, Goel A.

Cancer Res. 2010 Aug 15;70(16):6609-18. doi: 10.1158/0008-5472.CAN-10-0622.

17.

[A new quantitative DNA-methylation analysis of MSI colorectal cancers helps to separate sporadic colorectal cancers from HNPCC-candidates].

Bettstetter M, Rümmele P, Hofstädter F, Dietmaier W.

Verh Dtsch Ges Pathol. 2006;90:236-43. German.

PMID:
17867602
18.

Promoter hypermethylation downregulates RUNX3 gene expression in colorectal cancer cell lines.

Ku JL, Kang SB, Shin YK, Kang HC, Hong SH, Kim IJ, Shin JH, Han IO, Park JG.

Oncogene. 2004 Sep 2;23(40):6736-42.

PMID:
15273736
19.

CpG island promoter hypermethylation of a novel Ras-effector gene RASSF2A is an early event in colon carcinogenesis and correlates inversely with K-ras mutations.

Hesson LB, Wilson R, Morton D, Adams C, Walker M, Maher ER, Latif F.

Oncogene. 2005 Jun 2;24(24):3987-94.

PMID:
15806169
20.

A panel of genes methylated with high frequency in colorectal cancer.

Mitchell SM, Ross JP, Drew HR, Ho T, Brown GS, Saunders NF, Duesing KR, Buckley MJ, Dunne R, Beetson I, Rand KN, McEvoy A, Thomas ML, Baker RT, Wattchow DA, Young GP, Lockett TJ, Pedersen SK, Lapointe LC, Molloy PL.

BMC Cancer. 2014 Jan 31;14:54. doi: 10.1186/1471-2407-14-54.

Items per page

Supplemental Content

Support Center